日本抗リウマチ薬市場規模、シェア、競争環境、トレンド分析レポート：疾患タイプ別（変形性関節症、関節リウマチ、痛風、ループス、その他）、薬剤クラス別（疾患修飾性抗リウマチ薬（DMARDs）、非ステロイド性抗炎症薬（NSAIDs）、コルチコステロイド、JAK阻害薬、その他）、販売チャネル別（処方薬、市販薬）： 2026年から2035年までの機会分析および業界予測

レポートID : ROJP1225966 | 最終更新 : 2025年12月 | フォーマット : : :

JAPAN ANTI-RHEUMATIC DRUG MARKET REPORT - TABLE OF CONTENTS

1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY

4. VOICE OF CUSTOMER

5. MARKET DYNAMICS

5.1. Market Overview
5.2. Demand Supply Analysis
5.3. Import and Export Analysis
5.4. Value Chain Analysis
5.5. Porter’s Five Forces Analysis
5.6. PESTLE Analysis
5.7. Pricing Analysis
5.8. Market Dynamics
5.9 MARKET DRIVERS
- 5.9.1 Growth in geriatric population across Japan
5.10 MARKET RESTRAINTS
- 5.10.1 Patent expirations of blockbuster drugs
5.11 MARKET OPPORTUNITY
- 5.11.1 High growth potential in Japan
5.12 PORTER'S FIVE FORCE ANALYSIS
- 5.12.1 Bargaining Power of Buyers/Consumers
- 5.12.2 Bargaining Power of Suppliers
- 5.12.3 Threat of New Entrants
- 5.12.4 Threat of Substitute Products
- 5.12.5 Intensity of Competitive Rivalry

6. MARKET SEGMENTATION (Market Size by Value - USD (2026-2035)

6.1 By Type of Disease
- 6.1.1. Osteoarthritis
- 6.1.2. Rheumatoid Arthritis
- 6.1.3. Gout
- 6.1.4. Lupus
- 6.1.5. Others
6.2 By Drug Class
- 6.2.1. Disease-modifying Anti-Rheumatic Drugs {DMARDs}
- 6.2.2. Nonsteroidal Anti-inflammatory Drugs {NSAIDs}
- 6.2.3. Corticosteroids
- 6.2.4. JAK Inhibitor
- 6.2.5. Others
6.3 By Sales Channel
- 6.3.1. Prescription-based Drugs
- 6.3.2. Over-the-counter {OTC}
6.4 By Region
- 6.4.1. North [Hokkaido and Tohoku]
- 6.4.2. Central [Kanto and Chubu]
- 6.4.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]